Avalyn Pharma touts study of aerosolized pulmonary fibrosis treatment

Avalyn Pharma announced today that it observed statistically significant success in a study of its aerosolized pulmonary fibrosis treatment.

Seattle-based Avalyn presented data from a 24-week Phase 1/2 clinical study at the ISAM conference in Boise, Idaho. The data covered two dose regimens of AP01, a formulation of pirfenidone optimized for delivery through inhalation in patients with idiopathic pulmonary fibrosis (IPF), according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0